In the realm of targeted therapy, our prior research indicated that over one-fourth of patients with epidermal growth factor receptor (EGFR)-mutant metastatic NSCLC receiving third-generation EGFR tyrosine kinase inhibitors (TKIs) exhibited ORD at the peak response to EGFR-TKIs [10]. Here, EGFR is linked to non-small cell lung carcinoma.